|1.||Chuang, Lee-Ming: 7 articles (01/2015 - 04/2008)|
|2.||Chiu, Yen-Feng: 7 articles (01/2015 - 12/2006)|
|3.||Quertermous, Thomas: 6 articles (01/2015 - 03/2005)|
|4.||Kim, Young-Hoo: 6 articles (11/2013 - 09/2009)|
|5.||Kim, Hee Joong: 5 articles (01/2013 - 03/2005)|
|6.||Yoo, Jeong Joon: 5 articles (01/2013 - 03/2005)|
|7.||Ho, Low-Tone: 5 articles (07/2012 - 02/2006)|
|8.||Capello, William N: 5 articles (02/2012 - 12/2002)|
|9.||Kyotani, Tomohiro: 5 articles (07/2006 - 03/2005)|
|10.||Hung, Yi-Jen: 4 articles (01/2015 - 12/2006)|
03/01/1991 - "We confirmed that contact irradiation with a cone-shaped sapphire probe provides adequate incision and lysis at lower power levels, and that this method is an effective treatment for ovarian endometriosis."
06/01/1990 - "We confirmed that contact irradiation with a cone-shaped sapphire probe provides an adequate incision and lysis at low power levels and that this method is an effective treatment for ovarian endometriomas."
06/01/1989 - "Thirty-eight patients had laparoscopic treatment of endometriosis by the use of the Nd:YAG laser, combined with a fiber-optic cable equipped with sapphire contact tips. "
03/01/1989 - "Laparoscopic laser treatment of endometriosis with the Nd:YAG sapphire probe."
03/01/1989 - "Laparoscopic surgery with the Nd:YAG laser generator and a sapphire probe was performed in 43 women for relief of pain and/or infertility associated with endometriosis and in two other women for treatment of an asymptomatic adnexal enlargement. "
09/01/2013 - "Similar results were obtained in a trial comparing FloSeal versus infrared-sapphire coagulator during open renal tumor enucleation. "
02/01/2001 - "A task exposure database (TED) was developed to facilitate data collation for construction of a task exposure matrix (TEM) for Healthwise, a series of studies on cancer and respiratory morbidity in the alumina and primary aluminium industry. "
12/16/2015 - "Herein, we report the fabrication of a novel nanomaterial, so-called anodic alumina nanotubes (AANTs) for proof-of-concept cancer therapy by targeting cell signaling networks. "
12/16/2015 - "Bioinert Anodic Alumina Nanotubes for Targeting of Endoplasmic Reticulum Stress and Autophagic Signaling: A Combinatorial Nanotube-Based Drug Delivery System for Enhancing Cancer Therapy."
08/26/2015 - "In Vitro Biocompatibility of Surface-Modified Porous Alumina Particles for HepG2 Tumor Cells: Toward Early Diagnosis and Targeted Treatment."
|3.||Carotid Stenosis (Carotid Artery Stenosis)
09/01/2008 - "This review will summarize the results of randomized controlled trials (CAVATAS, WALLSTENT, SAPPHIRE, EVA-3S, SPACE, and CaRESS) as well as pivotal carotid registry studies (ARCHeR, BEACH, CAPTURE, CASES-PMS, CREATE, and CABernET) intended to evaluate the safety and efficacy of CEA and CAS in treatment of carotid stenosis. "
03/01/2015 - "The generalizability of trials like the SAPPHIRE or CREST to the Medicare population may be limited, underscoring the need to evaluate real-world effectiveness of carotid stenosis treatments."
03/01/2015 - "Indications and therapeutic management of carotid stenosis in high-risk patients: SAPPHIRE and beyond."
06/01/2007 - "Randomized trials like the SAPPHIRE trial have demonstrated that CAS is not inferior to carotid endarterectomy (CEA) in the treatment of carotid artery stenosis, and maybe even superior in high-risk symptomatic patients. "
07/01/2005 - "The SAPPHIRE trial compared the results of carotid endarteriectomy to those of carotid artery stenting with an emboli-protection device in patients with carotid artery stenosis and coexisting conditions that potentially increased the risk posed by endarteriectomy. "
05/01/2004 - "In 121 patients excluded on the basis of synchronous or immediate subsequent operations, who also would have been excluded from SAPPHIRE, the overall rates for stroke (1.65%; P =.69), death (1.65%; P =.09), and MI (0.83%; P =.71) were not significantly different from those in the study population. "
02/01/2011 - "Similarly, CAS was associated with 19%, 38%, 24%, and 48% increases in the intermediate to long-term outcomes of SAPPHIRE-like outcome, periprocedural death or stroke and ipsilateral stroke thereafter, death or any stroke, and any stroke, respectively. "
11/01/2006 - "In fact, 71% of patients in SAPPHIRE were asymptomatic in whom there was an average 6% 30-day death/stroke rate. "
07/01/2003 - "After similar blunting, all instruments were resharpened either with 10 strokes using an Arkansas fine-grit sharpening stone (AR), or with 7 strokes using a high-grit and -density aluminum oxide stone (CH). "
06/29/2010 - "All strokes to 30 days plus ipsilateral stroke between 31 and 360 days with CASES-PMS (5.4%) was similar to the rate seen with the SAPPHIRE trial stent cohort (4.9%). "
05/01/2012 - "Both the alumina-reduced and conventional surface acetabular cups can be used with confidence in primary THA for osteoarthritis, although longer-term studies are required to confirm these findings."
04/01/2001 - "The first 48 consecutive patients (50 hips) with osteoarthritis who had had primary total hip arthroplasty using the Cerafit Multicone stem and the Cerafit Triradius-M press-fit cup with alumina-alumina pairing (Ceraver Osteal, Paris, France) were followed-up for a mean of 2.3 years (2 to 2.5 years). "
10/01/1992 - "The use of a total hip prosthesis with an alumina ceramic head in THA is likely to lead to excellent results for patients with osteoarthrosis of the hip."
11/01/2006 - "Seventy patients with osteonecrosis of the femoral head (seventy-nine hips) received a cementless alumina-on-alumina bearing system and were directly matched to seventy-six patients with osteoarthritis of the hip (seventy-nine hips) who were managed with the same implant. "
09/01/2002 - "The aim of this work was to study the behavior of an inert porous alumina ceramic spacer used with a plate fixation for open-wedge tibial valgus osteotomy in patients with osteoarthritis of the knee and genu varum. "
|7.||Proteins (Proteins, Gene)
|9.||Aluminum Oxide (Sapphire)
|1.||Angioplasty (Angioplasty, Transluminal)
|5.||Transplantation (Transplant Recipients)